Hypertriglyceridemia: the importance of identifying patients at risk

Postgraduate Medicine

Volumn 128, Issue 8, 2016, Pages 848-858

  Kushner, Pamela A ^a   Cobble, Michael E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Canyons Medical Center   (United States)

Author keywords

Coronary artery disease; diabetes; hypertriglyceridemia; pancreatitis

Indexed keywords

FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL; ANTILIPEMIC AGENT;

CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIET; DISEASE CLASSIFICATION; ENDOCRINE DISEASE; ETHNICITY; HUMAN; HYPERTRIGLYCERIDEMIA; INCIDENCE; INHERITANCE; LIFESTYLE; LIFESTYLE MODIFICATION; MILD RENAL IMPAIRMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PANCREATITIS; REVIEW; WEIGHT REDUCTION; ANCESTRY GROUP; BLOOD; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HYPERCHOLESTEROLEMIA; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY; RISK FACTOR;

CARDIOVASCULAR DISEASES; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS, TYPE 2; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; LIFE STYLE; NON-ALCOHOLIC FATTY LIVER DISEASE; PANCREATITIS; RENAL INSUFFICIENCY; RISK FACTORS; WEIGHT LOSS;

EID: 84991039918     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.1080/00325481.2016.1243005     Document Type: Review

References (76)

1. M.J.Chapman, H.N.Ginsberg, P.Amarenco, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease:evidence and guidance for management. Eur Heart J. 2011;32:1345–1361.
2. C.Andersson, A.Lyass, R.S.Vasan, et al. Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study. Am Heart J. 2014;168:878–883.
3. T.A.Jacobson, M.K.Ito, K.C.Maki, et al. National lipid association recommendations for patient-centered management of dyslipidemia:part 1–full report. J Clin Lipidol. 2015;9:129–169.
4. M.Miller, N.J.Stone, C.Ballantyne, et al. Triglycerides and cardiovascular disease:a scientific statement from the American Heart Association. Circulation. 2011;123:2292–2333.
5. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421.
6. L.Berglund, J.D.Brunzell, A.C.Goldberg, et al. Evaluation and treatment of hypertriglyceridemia:an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:2969–2989.
7. P.Jellinger, D.Smith, A.Mehta, et al. American association of clinical endocrinologists’ guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012;18:1–78.
8. J.B.Christian, N.Bourgeois, R.Snipes, et al. Prevalence of severe (500 to 2,000 mg/dl) hypertriglyceridemia in United States adults. Am J Cardiol. 2011;107:891–897.
9. M.Carroll, B.Kit, D.Lacher Trends in elevated triglyceride in adults:United States, 2001–2012. NCHS Data Brief. 2015;1–8.
10. J.Pang, D.C.Chan, G.F.Watts. Origin and therapy for hypertriglyceridaemia in type 2 diabetes. World J Diabetes. 2014;5:165–175.
11. D.S.Fredrickson. An international classification of hyperlipidemias and hyperlipoproteinemias. Ann Intern Med. 1971;75:471–472.
12. A.Brahm, R.A.Hegele. Hypertriglyceridemia. Nutrients. 2013;5:981–1001.
13. R.N.Pejic, D.T.Lee. Hypertriglyceridemia. J Am Board Fam Med. 2006;19:310–316.
14. J.C.Cohen, E.Boerwinkle, T.H.MosleyJr., et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–1272.
15. B.F.Voight, G.M.Peloso, M.Orho-Melander, et al. Plasma HDL cholesterol and risk of myocardial infarction:a mendelian randomisation study. Lancet. 2012;380:572–580.
16. R.Do, C.J.Willer, E.M.Schmidt, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45:1345–1352.
17. Centers for Disease Control and Prevention. Prevalence of abnormal lipid levels among youths — United States, 1999–2006. MMWR Morb Mortal Wkly Rep. 2010;59:29–33.
18. C.S.Fox, J.M.Massaro, U.Hoffmann, et al. Abdominal visceral and subcutaneous adipose tissue compartments:association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116:39–48.
19. S.Subramanian, A.Chait. Hypertriglyceridemia secondary to obesity and diabetes. Biochim Biophys Acta. 2012;1821:819–825.
20. H.E.Resnick, G.L.Foster, J.Bardsley, et al. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999–2002:the National Health and Nutrition Examination Survey. Diabetes Care. 2006;29:531–537.
21. S.Yamamoto, V.Kon. Mechanisms for increased cardiovascular disease in chronic kidney dysfunction. Curr Opin Nephrol Hypertens. 2009;18:181–188.
22. D.E.Weiner, M.J.Sarnak. Managing dyslipidemia in chronic kidney disease. J Gen Intern Med. 2004;19:1045–1052.
23. B.H.Prinsen, M.G.dS-vdV, E.J.De Koning, et al. Hypertriglyceridemia in patients with chronic renal failure:possible mechanisms. Kidney Int Suppl. 2003;63:S121–S124.
24. G.Penno, A.Solini, G.Zoppini, et al. Hypertriglyceridemia is independently associated with renal, but not retinal complications in subjects with Type 2 diabetes:a cross-sectional analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study. PLoS One. 2015;10:e0125512.
25. A.E.Sumner, K.B.Finley, D.J.Genovese, et al. Fasting triglyceride and the triglyceride-HDL cholesterol ratio are not markers of insulin resistance in African Americans. Arch Intern Med. 2005;165:1395–1400.
26. S.Chhabra, R.Narang, L.R.Krishnan, et al. Apolipoprotein C3 SstI polymorphism and triglyceride levels in Asian Indians. BMC Genet. 2002;3:9.
27. J.Fulcher, R.O’Connell, M.Voysey, et al. Efficacy and safety of LDL-lowering therapy among men and women:meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397–1405.
28. C.Baigent, A.Keech, P.M.Kearney, et al. Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.
29. M.A.Austin, J.E.Hokanson, K.L.Edwards. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81:7B–12B.
30. B.G.Nordestgaard, M.Benn, P.Schnohr, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. Jama. 2007;298:299–308.
31. A.Varbo, M.Benn, A.Tybjaerg-Hansen, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427–436.
32. M.Miller, C.P.Cannon, S.A.Murphy, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51:724–730.
33. G.G.Schwartz, M.Abt, W.Bao, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015;65:2267–2275.
34. P.C.Deedwania, J.Shepherd, A.Breazna, et al. Effect of high-dose atorvastatin on the cardiovascular risk associated with individual components of metabolic syndrome:a subanalysis of the Treating to New Targets (TNT) study. Diabetes Obes Metab. 2016;18:56–63.
35. O.Faergeman, I.Holme, R.Fayyad, et al. Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease. Am J Cardiol. 2009;104:459–463.
36. R.Klempfner, A.Erez, B.Z.Sagit, et al. Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease:twenty-two-year follow-up of the Bezafibrate infarction prevention study and registry. Circ Cardiovasc Qual Outcomes. 2016;9:100–108.
37. M.Miller, A.Seidler, A.Moalemi, et al. Normal triglyceride levels and coronary artery disease events:the Baltimore Coronary Observational Long-Term Study. J Am Coll Cardiol. 1998;31:1252–1257.
38. G.D.Kolovou, D.P.Mikhailidis, J.Kovar, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides:an expert panel statement. Curr Vasc Pharmacol. 2011;9:258–270.
39. B.G.Talayero, F.M.Sacks. The role of triglycerides in atherosclerosis. Curr Cardiol Rep. 2011;13:544–552.
40. S.Tenner, J.Baillie, J.DeWitt, et al. American College of Gastroenterology guideline:management of acute pancreatitis. Am J Gastroenterol. 2013;108:1400–1415.
41. S.K.Kota, S.K.Kota, S.Jammula, et al. Hypertriglyceridemia-induced recurrent acute pancreatitis:a case-based review. Indian J Endocrinol Metab. 2012;16:141–143.
42. W.Kimura, J.Mossner. Role of hypertriglyceridemia in the pathogenesis of experimental acute pancreatitis in rats. Int J Pancreatol. 1996;20:177–184.
43. S.M.Abd El-Kader, E.M.El-Den Ashmawy. Non-alcoholic fatty liver disease:the diagnosis and management. World J Hepatol. 2015;7:846–858.
44. K.G.Tolman, A.S.Dalpiaz. Treatment of non-alcoholic fatty liver disease. Ther Clin Risk Manag. 2007;3:1153–1163.
45. S.S.Martin, M.J.Blaha, M.B.Elshazly, et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol. 2013;62:732–739.
46. M.B.Elshazly, S.S.Martin, M.J.Blaha, et al. Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults:the VLDL-2 study (very large database of lipids). J Am Coll Cardiol. 2013;62:1960–1965.
47. R.K.Johnson, L.J.Appel, M.Brands, et al. Dietary sugars intake and cardiovascular health:a scientific statement from the American Heart Association. Circulation. 2009;120:1011–1020.
48. R.P.Mensink, P.L.Zock, A.D.Kester, et al. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins:a meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003;77:1146–1155.
49. D.S.Ludwig. The glycemic index:physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. Jama. 2002;287:2414–2423.
50. M.J.Dekker, T.E.Graham, T.C.Ooi, et al. Exercise prior to fat ingestion lowers fasting and postprandial VLDL and decreases adipose tissue IL-6 and GIP receptor mRNA in hypertriacylglycerolemic men. J Nutr Biochem. 2010;21:983–990.
51. K.Tambalis, D.B.Panagiotakos, S.A.Kavouras, et al. Responses of blood lipids to aerobic, resistance, and combined aerobic with resistance exercise training:a systematic review of current evidence. Angiology. 2009;60:614–632.
52. N.J.Stone, J.G.Robinson, A.H.Lichtenstein, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889–2934.
53. S.J.Nicholls, G.Brandrup-Wognsen, M.Palmer, et al. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105:69–76.
54. Food and Drug Administration. Withdrawal of Approval of Indications Related to the Coadministration With Statins in Applications for Niacin Extended-Release Tablets and Fenofibric Acid Delayed-Release Capsules. Available from:https://www.federalregister.gov/articles/2016/04/18/2016-08887/abbvie-inc-et-al-withdrawal-of-approval-of-indications-related-to-the-coadministration-with-statins#h-11
55. B.Staels, J.Dallongeville, J.Auwerx, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088–2093.
56. V.S.Kamanna, M.L.Kashyap. Mechanism of action of niacin. Am J Cardiol. 2008;101:20B–6B.
57. R.R.Koski. Omega-3-acid ethyl esters (Lovaza) for severe hypertriglyceridemia. Pharm Ther. 2008;33:271–303.
58. D.J.Maron, S.Fazio, M.F.Linton. Current perspectives on statins. Circulation. 2000;101:207–213.
59. AstraZeneca. Epanova prescribing information; [cited 2014 Mar]. Available from:http://www1.astrazeneca-us.com/pi/epanova.pdf
60. Amarin Corporation. Vascepa prescibing information; [cited 2014 Nov]. Available from:www.vascepa.com/full-prescribing-information.pdf
61. GlaxoSmithKline. Lovaza prescribing information; [cited 2014 Mar]. Available from:https://www.gsksource.com/gskprm/htdocs/documents/LOVAZA-PI-PIL.PDF
62. Trygg Pharma. Omtryg prescribing information; [cited 2014 Apr]. Available from:http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204977s000lbl.pdf
63. M.H.Frick, O.Elo, K.Haapa, et al. Helsinki Heart Study:primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237–1245.
64. H.B.Rubins, S.J.Robins, D.Collins, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410–418.
65. V.Manninen, L.Tenkanen, P.Koskinen, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992;85:37–45.
66. S.J.Robins, D.Collins, J.T.Wittes, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events:VA-HIT:a randomized controlled trial. Jama. 2001;285:1585–1591.
67. A.Keech, R.J.Simes, P.Barter, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):randomised controlled trial. Lancet. 2005;366:1849–1861.
68. H.N.Ginsberg, M.B.Elam, L.C.Lovato, et al.; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–1574.
69. W.E.Boden, J.L.Probstfield, T.Anderson, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267.
70. M.J.Landray, R.Haynes, J.C.Hopewell, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–212.
71. M.Yokoyama, H.Origasa, M.Matsuzaki, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS):a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090–1098.
72. C.Wanner, M.Tonelli. KDIGO Clinical Practice Guideline for Lipid Management in CKD:summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85:1303–1309.
73. Clinicaltrials.gov. A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event. (REDUCE-IT); 2015. Available from:https://clinicaltrials.gov/ct2/show/NCT01492361
74. Clinicaltrials.gov. Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH); 2015. Available from:https://clinicaltrials.gov/ct2/show/NCT02104817
75. O.N.Akram, A.Bernier, F.Petrides, et al. Beyond LDL cholesterol, a new role for PCSK9. Arterioscler Thromb Vasc Biol. 2010;30:1279–1281.
76. S.E.Gryn, R.A.Hegele. Novel therapeutics in hypertriglyceridemia. Curr Opin Lipidol. 2015;26:484–491.